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Case presentation
A 52-year-old man with end-stage renal disease has been receiving
hemodialysis treatments 3 times weekly for 8 years. He currently works
35 hours per week as a maintenance electrician, does not smoke, and
drinks an occasional beer. The cause of his renal failure is presumed to
be glomerulonephritis, although the diagnosis has not been established.
He was first noted to have proteinuria while in the armed services in
1956. A renal biopsy was attempted but was unsuccessful. The patient
states that everything "cleared up," but no further medical followup
occurred until January 1975, when he sought medical attention because
of shortness of breath. At that time he was found to have pulmonary
edema and a blood pressure of 230/130 mm Hg. Serum creatinine
concentration was 4.4 mg/dl and he had nephrotic-range proteinuria.
His blood pressure was controlled with methyldopa, hydralazine, and
furosemide, but nonetheless he developed progressive renal failure. In
mid-1975 the serum creatinine was 4.1 mg/dl; sodium, 140 mEq/Iiter;
potassium, 4.7 mEq/liter; total CO2. 20 mmol/liter; and chloride, 101
mEq/liter. By November 1976, serum creatinine had risen to 14.1 mg/dl;
BUN, 140 mgldl; sodium, 142 mEq/liter; potassium, 4.4 mEq/liter; total
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CO2. 8 mmol/liter; and chloride, 114 mEq/liter. Dialysis was begun with
a standard hollow-fiber kidney, using an acetate-containing bath solu-
tion. Soon thereafter, because of persistently high blood urea nitrogen
levels before dialysis, a high-clearance dialysis cartridge was substitut-
ed. He currently is dialyzed using a cuprophane hollow-fiber kidney
with a urea clearance of 168 mI/mm (Erika B-lU) for 4.5 hours 3 times
weekly. His dialysis bath solution contains acetate, 37 mEq/liter;
sodium, 135 mEq/liter; potassium, 2 mEq/liter; chloride, 105 mEq/liter;
calcium, 3.5 mEq/liter; magnesium, 1.5 mEq/liter; and dextrose, II
mM. He is a large, muscular man who weighs 110 kg, and who finds it
difficult to restrict his protein intake.
Since beginning dialysis, predialysis total CO2 content has ranged
from 14 to 20 mmol/liter, but on most occasions has been 15 to 17 mmol/
liter. A representative predialysis blood sample in 1977 showed the
following electrolyte concentrations: sodium, 140 m Eq/liter, potassium,
6.0 mEq/liter; total C02, 15 mmol/liter; chloride, 103 mEq/liter. In 1981,
a predialysis blood sample drawn from his fistula for acid-base analysis
showed the following values: pH, 7.33; PaCO2, 33 mm Hg; and
calculated bicarbonate concentration, 16.9 mEq/liter. In 1982, repre-
sentative predialysis values showed a serum creatinine of 16.8 mg/dl;
BUN, 91 mgldl; sodium, 143 mEq/liter; potassium, 5.7 mEq/liter; total
CO2. 16 mmollliter, and chloride, 109 mEq/liter. In January 1985, his
serum creatinine was 19.2 mg/dl; BUN, 104 mg/dl; sodium, 142 mEq/
liter; potassium, 4.8 mEq/liter; total C02, 14 mmol/liter; and chloride,
105 mEq/liter.
Except for early access problems, the patient's course has been
relatively uncomplicated. During his first 3 years of hemodialysis, he
was hospitalized 7 times for fistula revisions. Over the last 5 years, he
has been hospitalized only twice, once for revision of a fistula, and once
for a foot infection secondary to a work-related injury. He remains
overweight and has developed adult-onset diabetes, as well as hyper-
triglyceridemia, both controlled with diet alone. His predialysis blood
pressure ranges from 140—150/80—90mm Hg. At the end of dialysis, his
blood pressure is typically 130/80 mm Hg. He has taken methyldopa
intermittently for blood pressure control, but currently is not taking any
antihypertensive medication. In 1981, SGOT and SGPT increased
significantly for a period of several months; it was presumed that he had
contracted non-A, non-B hepatitis. This problem resolved without
hospitalization or specific treatment.
Serum phosphate level has remained persistently elevated. The
patient currently takes a combination of calcium carbonate (Tums) and
aluminum hydroxide (Amphogel) for this problem. The most recent
values for calcium and phosphorus were 9.7 and 6.2 mg/dl, respectively.
A parathyroid hormone level was 2.5 ng/ml in 1980; at that time the
serum ionized calcium was 2.3 mEq/liter. The alkaline phosphatase was
in the normal range until this year, when it increased to 141 IU. Bone
films in 1980 showed some demineralization but no evidence of parathy-
roid bone disease.
The patient generally feels well. He tolerates the removal of I to 3
liters of fluid at each dialysis treatment, although he occasionally feels
"washed out." He has not required transfusions, and he maintains a
hematocrit from 29% to 32%. He has decided not to pursue the
possibility of a kidney transplant.
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Fig. 1. Distribution of predialysis plasma bicarbonate concentration in
48 patients receiving chronic hemodialysis therapy. All patients were
dialyzed against a single-pass bath containing acetate, 37 mEq/liter, and
no bicarbonate. The mean value SD is shown above the graph.
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Fig. 2. Relationship between plasma bicarbonate concentration and
plasma hydrogen ion concentration (left-hand ordinate) or pH (right-
hand ordinate) in 48 patients receiving chronic hemodialysis therapy.
Mean pH and hydrogen ion concentration (± SD) are shown above the
graph. The line drawn through the points was calculated using linear
regression analysis.
Discussion
DR. F. JOHN GENNARI (Director, Nephrology Division, Uni-
versity of Vermont College of Medicine, Burlington, Vermont):
As this patient illustrates, metabolic acidosis is present in most
patients undergoing hemodialysis treatment for end-stage renal
disease. In this review, I will characterize the nature of this
acid-base disturbance, address the question of its cause, and
consider the potential short-term and long-term adverse effects
of this disorder. If these issues can be clarified, a rational basis
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Fig. 3. Schematic representation of acid balance in normal individuals.
The acid produced is excreted quantitatively to maintain balance.
Because renal acid excretion is not immediate, the hydrogen ions
produced are buffered until they can be excreted. Intracellular, extra-
cellular, and bone buffer substances contribute to this normal buffer
response. When the acid is excreted, new bicarbonate ions are added to
the body, increasing pH. As a result, body buffers are back-titrated to
their original condition and body buffer stores are maintained. (Modi-
fied from Ref. 20.)
can be developed for deciding whether specific treatment for
this disorder is necessary.
First, I would like to put the problem into quantitative
perspective. Several years ago, I assessed the acid-base status
of the patients in our dialysis unit. Blood was obtained for pH
and PCO2 measurements from the A-V fistulas of 48 stable
7.25 outpatients just before dialysis. Mean calculated plasma bicar-
bonate concentration was 17.8 2.2 (SD) mEqlliter, with 45 of
48 patients having values between 14 and 20 mEq/liter (Fig. I).
7.30 This mean value is comparable to reports in the literature from
other centers; predialysis bicarbonate concentration has been
found to range from 16 to 22 mEq/liter [1—7]. This range reflects,
in large part, differences in dialysis techniques. Predialysis
740 bicarbonate concentration is determined not only by patient-
specific factors, but also by the type of dialysis treatment the
patient receives. The low bicarbonate concentration is clearly
associated with acidemia. As Figure 2 shows, hydrogen ion
concentration increases as bicarbonate concentration falls. The
mean value is 46 nEq/liter or a pH of 7.34. As might be
expected, PCO2 decreases in direct relation to the fall in
bicarbonate, by approximately 1 mm Hg per mEq/liter. This
change is consistent with the respiratory response typically
seen in uncomplicated metabolic acidosis.
Having now characterized this acid-base disturbance in a
traditional fashion, I would like to take a slightly untraditional
turn. I want to ask next whether the metabolic acidosis in
hemodialysis patients is one in which continued positive acid
balance occurs, or whether net hydrogen ion balance over the
long term is essentially zero. These two alternatives have far
different implications.
Hydrogen ion balance
For background to this issue, I will review briefly acid
balance in normal individuals (Fig. 3). As a result of metabolism
of the foods we ingest and an associated gastrointestinal alkali
loss, approximately 50 to 100 mEq of hydrogen ions are added
Mean 17.8 2.2 mEqL
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to the body each day; these must be excreted by the kidney to
maintain acid balance. The addition of these acids is termed
endogenous acid production. Careful balance studies in humans
have demonstrated, in fact, that an equivalent amount of acid is
excreted by the kidney each day [8, 9]. Because renal acid
excretion is not immediate, the hydrogen ions produced by
metabolism must be buffered transiently by proton acceptors in
the body. As Figure 3 illustrates, a variety of extracellular,
intracellular, and bone-buffer substances contribute to this
process. At a normal bicarbonate concentration, extracellular
bicarbonate stores account for slightly less than one-half the
buffer response [10—12]. When bicarbonate is the buffer, this
anion is consumed because the carbonic acid formed is volatile
and excreted as carbon dioxide via the lungs. Other buffers can
be renewed by back-titration with alkali. As the kidney excretes
the acid load, equivalent amounts of new bicarbonate are
generated that titrate non-bicarbonate buffers to their original
state and replenish body bicarbonate stores. In patients with
renal failure, administered bicarbonate serves precisely the
same purpose as does renal generation of bicarbonate by acid
excretion.
Metabolic acidosis in renal failure
When renal mechanisms for acid excretion fail, acid neces-
sarily is retained because daily production continues. Despite
continued acid retention, the plasma bicarbonate level eventu-
ally stabilizes, and bone carbonate becomes an increasingly
important buffer substance [13—IS]. In patients with untreated
uremic acidosis, bone carbonate stores are significantly de-
creased [14, 15]. Another example of metabolic acidosis with
continued acid retention is distal renal tubular acidosis (RTA);
bone disease is a characteristic feature of long-standing distal
RTA [16]. What is not often realized is that virtually all the
experimental work in chronic metabolic acidosis has been
carried out using NH4CI or HCI administration, a model in
which continued acid retention also occurs [17, 18]. When HCI
or its equivalent is administered daily, approximately 10% to
20% of the administered hydrogen ion is retained each day,
even in the so-called steady state [17, 18]. In this model,
Lemann, Litzow, and Lennon documented continued negative
calcium balance in humans with chronic metabolic acidosis
[17].
Chronic metabolic acidosis, however, also can occur without
continued acid retention. Proximal RTA, or bicarbonate-wast-
ing RTA, is an example [16, 19]. This relatively unusual
disorder is characterized by defective bicarbonate reabsorption
by the kidney; serum bicarbonate concentration falls to a level
at which renal bicarbonate reabsorption can be accomplished
and normal acid excretion can occur. In the steady state,
individuals with proximal RTA are in acid balance, albeit at a
low plasma bicarbonate concentration. In the absence of any
associated tubular defects, this disorder produces a stable,
long-term chronic metabolic acidosis with few adverse effects
and no metabolic bone disease [19]. The only adverse effect
seen is growth retardation. As I will demonstrate in this review,
the metabolic acidosis occurring in patients receiving dialysis
treatment is, by its very nature, quite similar to proximal RTA.
A logical analysis of the events occurring during dialysis
indicates that, over the long term, acid balance must be
maintained. I introduced this concept previously [20], but will
Fig. 4. Schematic representation of the interaction between the patient
and dialysis membrane during dialysis against an acetate-containing
bath. As the blood travels through the dialyzer, acetate diffuses in and
bicarbonate diffuses out. In the body, acetate is metabolized forming
new bicarbonate. See text for a full description of these events.
(Modified from Ref. 20.)
review it in greater detail here. My conclusion that acid balance
is maintained in dialysis patients is supported by studies in
which measured alkali addition during dialysis is compared with
estimated acid production [1, 21]. Despite these measurements,
there is continued concern that the acidosis in patients on
dialysis, such as that in the patient presented here, will exacer-
bate bone mineral loss [1,2,5,21,22].There is little evidence to
support this notion.
Bicarbonate and acetate transfer during dialysis
To understand the state of acid balance in dialysis patients,
we need to review the way that alkali is administered during
hemodialysis treatments. Figure 4 illustrates the exchange and
metabolic events that occur when a patient is dialyzed against a
single-pass bath containing acetate but no bicarbonate. In the
dialysis cartridge, bicarbonate diffuses out and acetate diffuses
in, so that the blood leaving the dialysis cartridge has a low
bicarbonate and a high acetate concentration [23, 24]. The pH
does not fall because CO2 also diffuses out; the PCO2 in the
blood that returns to the patient falls to less than 20 mm Hg [23].
In the body, acetate is metabolized rapidly, generating new
bicarbonate, so that the bicarbonate concentration in the blood
reentering the dialyzer is approximately 20 mEq/liter, and the
acetate concentration is approximately 5 mEq/liter. Obviously
the system is designed so that more acetate enters than bicar-
bonate leaves. The overall transfer either of acetate in or
bicarbonate out can be calculated from its dialysance and the
concentration gradient (AC) across the membrane (mass trans-
fer = dialysance x AC). The dialysance of each of these anions
is determined by the characteristics of the membrane, the rate
of plasma ultrafiltration, and the flow rates of the blood and
bath fluid through the cartridge. The dialysance of bicarbonate
is approximately equal to the dialysance of urea; the dialysance
of acetate is somewhat lower [1, 4, 23, 25]. We set the
HC03 = 20 mmols/L
CH3COO = 5 mmols/L
pH = 7.39
HC03 = 8 mmols/L
CH3COO 15 mmols/L
pH = 7.44
HC03
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concentration of acetate in the bath so that, for a given patient,
acetate delivery is relatively constant for each dialysis. On the
other hand, the bicarbonate concentration in the blood is not
predetermined. It varies depending on the interplay between
the rate of endogenous acid production and the rate of net alkali
gain during dialysis.
Feedback regulation of bicarbonate concentration
Let's look a little more closely at that interplay. Acetate
delivery is constant, but the rate of bicarbonate loss across the
dialysis membrane varies inversely with the concentration of
bicarbonate entering the cartridge. Net alkali gain is the differ-
ence between acetate entry and bicarbonate loss; therefore,
more alkali is gained when plasma bicarbonate concentration is
low, and vice versa. To illustrate the effect of this unique
feedback system on predialysis bicarbonate concentration in a
more quantitative fashion. I present a hypothetical example,
shown in Table 1. In this example, I have estimated that 60
mmols of endogenous acid are generated by the patient each
day, which translates into 420 mmols/week. Although this
arbitrary value is in keeping with estimates obtained from the
protein catabolic rate [21], no one has actually measured
endogenous acid production in patients on dialysis. For the
purposes of this analysis, however, the precise numbers are
unimportant. As I will demonstrate, they only determine the
particular bicarbonate level at which a steady state is achieved.
The second important element in this analysis is a phenomenon
unique to dialysis patients. In the anuric patient, the anions of
the organic acids produced by metabolic processes are not lost
from the body, except during dialysis. In the interdialytic
period, they remain in the body and are available to accept
protons if they undergo further metabolism. During dialysis,
organic anion loss has been reported to range from 30 to 100
mmols per treatment [1, 21, 25]. Again the specific value used is
unimportant for the purposes of this analysis. Assuming a high
value of 100 mmols for each of three treatments per week and
adding this lost "potential alkali" to the hydrogen ions generat-
ed endogenously, we obtain the alkali needed in this example to
maintain balance, that is, 720 mmols/week. With 3 dialyses per
week, 240 mmols are needed per dialysis.
Given this alkali requirement for balance, and the specifica-
tions of the dialysis treatment shown in the table, one can
predict the steady-state predialysis bicarbonate concentration
that will ensue. In this example, we assume bicarbonate dialy-
sance to be 150 mI/mm and acetate dialysance 120 mI/mm; these
values are comparable to those reported for standard dialysis
cartridges [11. Bath acetate concentration is 37 mM, and the
system is assumed to have a single-pass bath. In such a dialysis,
plasma acetate concentration rises rapidly to 2 mM in the first
30 minutes of dialysis, and then reaches a steady-state value
close to 5 mM by the second or third hour [1, 4, 241. Acetate
entry in this example is calculated based on this profile of
plasma acetate concentration. During the course of the usual
dialysis, plasma bicarbonate concentration does not change
notably [1, 3, 25]. The increase occurs after dialysis as the 3 to 5
mmols/liter of acetate remaining in the blood are metabolized
[1]. Thus, bicarbonate loss is calculated on the basis of the
bicarbonate concentrations shown in the table. Bath bicarbon-
ate concentration is assumed to be zero.
Table I illustrates what happens over 4 hours of dialysis at
Table I. Acid balance in hemodialysis patients: Theoretic
considerations
A. Acid addition:
1. From diet 420 mmols/week
2. Organic anion loss during dialysis 300 mmols/week
Total = 720 mmols/week
B. Alkali required = 240 mmols/dialysis
(assuming 3 dialyses/week)
C. Dialysis specifications:
1. 4 hrs duration
2. Bath acetate = 37 mM
3. = 120 mI/mm; DHCO3- = 150 mllmin
Predialysis
Plasma HC03 Acetate in HC03 out Net alkali Alkali-240
mEq/L mmols
16 953 576 377 137
18 953 648 305 65
19 953 684 269 29
20 953 720 233 —7
22 953 792 161 —79
[HC03j
mEq/L
24
22
20
18
16
50 100
Endogenous acid production
mmols day
150
Fig. 5. Theoretical relationship between endogenous acid production in
mmols per day and predialysis plasma bicarbonate concentration in
patients being dialyzed 3 times weekly against a single-pass, acetate-
containing bath with constant dialysis characteristics. In this system,
long-term acid balance is zero, and predialysis bicarbonate concentra-
tion is determined by endogenous acid production.
varying predialysis plasma bicarbonate concentrations in this
example. In each instance, the acetate entry is the same
because we have set it. The amount of bicarbonate lost,
however, is determined by the plasma bicarbonate concentra-
tion. At a predialysis bicarbonate concentration of 16 mEq/liter,
377 mEq of net alkali is gained during dialysis; this amount is
approximately 137 mEq in excess of that required to maintain
balance. Thus, if the patient has this predialysis plasma bicar-
bonate level, the bicarbonate concentration should be higher at
the time of the next dialysis. At the other extreme shown in
Table 1, if the predialysis plasma bicarbonate concentration is
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Table 2. Cumulative H balance over one week in 8 patients
receiving acetate dialysis (three 4-hr treatments)a
Acid in
I. Endogenous acid productionb 375 32 (SE)
2. Lactate loss 57 4
3. 3-hydroxybutyrate loss 55 IS
Total 487 mmols
Alkali in
I. Acetate delivery 2341 183
2. Bicarbonate loss —1848 150
Hydrogen io
Total
n balance
493 mmols
—7 28
a From Ref. 21.
b Calculated as 0.77 times protein catabolic rate.
22 mEq/liter, only 161 mEq of net alkali will be gained; this
amount is less that that required to maintain balance. Thus,
unneutralized, retained hydrogen ion will cause the next predia-
lysis bicarbonate concentration to be lower. With time, predia-
lysis bicarbonate concentration, given the assumptions in this
example, will be maintained at somewhere between 19 and 20
mEq/liter. At this level, net alkali gain will equal acid produc-
tion, and long-term acid balance will be zero. A more elegant
model could be developed if one were to consider the distribu-
tion of acetate and bicarbonate across the red cell membrane,
but such refinements would not alter the overall conclusion
drawn from this analysis.
This analysis demonstrates that, with constant dialysis char-
acteristics, predialysis serum bicarbonate concentration is in-
versely related to endogenous acid production (Fig. 5). Al-
though positive acid balance occurs between each dialysis, by
definition long-term acid balance has to be zero. This theoreti-
cal model holds unless there is some sustained buffer disequilib-
rium in the body, that is, unless the serum bicarbonate concen-
tration does not reflect the status of other buffers in the body.
This possibility is exceedingly unlikely, As I noted earlier,
positive acid balance can continue in the face of a constant
serum bicarbonate concentration in patients with metabolic
acidosis due to renal insufficiency, distal RTA, or NH4CI
administration [13, 17, 181. In these instances, unrelenting acid
accumulation is never counterbalanced by new alkali genera-
tion. By contrast, patients receiving hemodialysis treatments do
not have a stable bicarbonate concentration. The bicarbonate
level rises after dialysis and gradually declines over the interval
between dialyses [4, 7]. In this setting, the fluctuating bicarbon-
ate concentration reflects the depletion of alkali stores between
dialyses and the replenishment of alkali stores during dialysis.
Estimates of acid balance in dialysis patients
My theoretical analysis is supported by measurements of
alkali addition during acetate dialysis [1, 21]. Vreman and
coworkers carried out measurements of net alkali gain and
organic anion loss during dialysis in 20 patients receiving
standard treatments against a single-pass acetate bath [1]. They
found that, on average, 278 mmols of alkali were gained and 100
mmols of organic anion were lost per dialysis treatment. Thus,
178 mmols of alkali were available to offset acid production in
the interdialytic interval. Net alkali addition, averaged over the
course of one week in these patients, was 74 mmols/day, a value
not significantly different from the estimated endogenous acid
production. Mean predialysis bicarbonate concentration in
these patients was 19.7 mEq/liter although, as in my survey,
there was wide variability of values among patients, from 16 to
25 mEq/liter. This variability probably is related in large part to
variations in the four types of dialysis cartridge used in the
patients studied and in the length of dialysis.
More recently, Gotch and colleagues carried out a similar
analysis in 8 patients [21]. The results, summarized in Table 2,
also show acid balance over a one-week period. To estimate
endogenous acid production in patients on dialysis, these
workers developed an empiric formula based on observations in
normal individuals. The authors reviewed the results of studies
in which nitrogen balance and net acid excretion were measured
under steady-state conditions, and they developed a coefficient
relating acid excretion (equivalent to acid production in the
steady state) to protein catabolic rate. Using this coefficient,
and calculating protein catabolic rate from urea kinetic analysis
in each of their dialysis patients, they derived a value for
endogenous acid production. If this value is at all in error, it
probably overestimates endogenous acid production; in individ-
uals with normal renal function, approximately 30% to 50% of
endogenous acid is due to organic acid production and excre-
tion of the organic anion [8, 9]. As I noted earlier, organic anion
loss in patients on dialysis only occurs during the dialysis
treatment, and it is accounted for separately (Tables I and 2).
The requirement for alkali was much lower in the studies by
Gotch and coworkers (Table 2) than it was in the studies by
Vreman and colleagues [1] because of major differences in
organic anion losses. The reason for this difference is unclear.
In the former study, only 3-hydroxybutyrate and lactate losses
were measured, whereas in the latter study, citrate, pyruvate,
and acetoacetate losses also were measured. However, 3-
hydroxybutyrate and lactate are the most important anions
quantitatively. The presence or absence of glucose in the bath
influences organic anion loss; acetoacetate and 3-hydroxybu-
tyrate losses are much greater if the bath contains no glucose,
presumably because of increased production of these two
organic acids during dialysis [261. In the study by Vreman and
coworkers, the bath contained no glucose; Gotch and cowork-
ers did not specify the bath glucose content. Both studies, of
course, suffer from the problem of having no direct measure-
ment of endogenous acid production. But I believe that their
estimates are probably close to the mark because, as I indicated
earlier, acid balance has to occur unless there is buffer disequi-
librium in the body.
Use of high-mass-transfer dial sis membranes
Despite this theoretical and experimental evidence for zero
acid balance, concern about metabolic acidosis in dialysis
patients has led investigators to attempt to increase plasma
bicarbonate concentration. One way of accomplishing this, in
theory, is to increase the bath acetate concentration or to use a
membrane with a higher acetate dialysance to deliver more of
this bicarbonate precursor. The limitation to this approach is
the rate at which the body can convert acetate to bicarbonate.
This rate appears to vary considerably from patient to patient
but, on average, ranges from 2.5 to 5 mmols/min [1, 4, 24].
Tolchin and coworkers demonstrated that this metabolic rate
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can be overwhelmed by increasing bath acetate concentration
and by using a high-mass-transfer dialysis cartridge [4]. In this
setting, plasma acetate continues to rise during dialysis, rather
than reaching a steady-state value. The rising plasma acetate
limits acetate transfer from bath to patient by reducing the
transmembrane concentration gradient for this anion. In addi-
tion, bicarbonate concentration falls, because of the high dialy-
sance of bicarbonate inherent in these membranes. The fall in
bicarbonate concentration occurs at the beginning of the treat-
ment, and further bicarbonate loss is minimized. The end result
of these effects on acetate and bicarbonate transfer is that net
alkali gain is roughly equivalent to that achieved with a standard
dialysis cartridge. At the end of dialysis, however, the patient is
left with a low bicarbonate concentration and a high acetate
concentration. From an acid-base standpoint, this is only
transiently deleterious. The rise in bicarbonate concentration
over the next few hours is directly proportional to the plasma
acetate concentration at the end of dialysis [1]. From the point
of view of the patient's symptoms during dialysis, however, this
state of affairs is probably not desirable. The issue of patient
symptoms is beyond the scope of the present review, but the
limitations of trying to increase acetate delivery are obvious.
Before leaving the topic of acetate dialysis, I want to review
acetate metabolism briefly. Acetate generates bicarbonate by
picking up a hydrogen ion as it is metabolized to acetyl
coenzyme A. Acetyl coenzyme A has many potential metabolic
fates, but which road it takes is unimportant, from an acid-base
perspective, so long as another organic acid is not the end
product. Mudge and coworkers demonstrated in 1949 that
acetate infusion was the equivalent of bicarbonate infusion in
humans [27], and recent studies in dialysis patients indicate that
90% to 100% of infused acetate produces bicarbonate [4]. A
major difference between bicarbonate and acetate is that ace-
tate metabolism produces calories as well as alkali. Acetate
metabolism accounts for up to 65% of the caloric needs during
dialysis [28]. Moreover, acetate metabolism has been shown to
stimulate organic acid production even when glucose is present
in the bath [22, 26]. Replacement of acetate with bicarbonate in
the bath blunts this stimulation but does not obliterate it [4, 22].
Bicarbonate supplementation/bicarbonate dialysis
Two other ways of raising plasma bicarbonate concentration
in hemodialysis patients are bicarbonate (or bicarbonate precur-
sor) administration and dialysis with bicarbonate in the bath.
Both maneuvers have been used. Van Stone gave 12 patients
the bicarbonate precursor sodium citrate, equivalent to 1 mEq/
kg body weight per day [2]. On average, the patients took 75%
of the dose, but even this amount should have been sufficient to
closely approximate daily endogenous acid production. With
this treatment, predialysis bicarbonate concentration increased
from 17 to 21 mEq/liter. The cost of this therapy was increased
weight gain between dialyses. Van Stone wondered why plasma
bicarbonate concentration didn't completely return to normal in
his patients. There are several explanations. The first I have
already dealt with: the higher the predialysis bicarbonate con-
centration, the less alkali gained during the dialysis treatment.
The second possibility is that daily bicarbonate administration
actually stimulates organic acid production, increasing the acid
load to be titrated. Bicarbonate administration has been shown
to stimulate organic acid production in fasting states or when
ketoacid production is increased [29—31]. The same effect of
bicarbonate on lactic acid production is well recognized in lactic
acidosis [32—34]. Van Stone did not measure organic anion loss
during dialysis, so this possibility remains. Although unlikely, it
is also possible that all the administered citrate was not ab-
sorbed from the gut. Van Stone postulates that bicarbonate
concentration might remain low because the administered bi-
carbonate is replenishing some depleted non-bicarbonate buffer
store, such as bone. Long-range studies are required to test this
hypothesis, but I think it is exceedingly unlikely for the reasons
discussed earlier.
The second option is the use of bicarbonate rather than
acetate in the bath. In the 'SOs and early '60s, this was the
standard approach to therapy. Because bicarbonate addition
results in calcium carbonate precipitation in a highly alkaline
medium, carbon dioxide had to be bubbled through the bath in
the old systems to lower pH. After Mion and colleagues
demonstrated in 1964 that acetate was a feasible alkali source
during dialysis, acetate rapidly replaced bicarbonate because of
its ease of delivery [35]. The use of bicarbonate as an alkali
source in dialysis bath solutions has re-emerged in the past
several years, and it now is used routinely for selected patients
[5, 6, 21, 22]. The requirement for CO2 has been bypassed by
adding the bicarbonate just before the bath enters the dialysis
cartridge. Obviously, one can raise the plasma bicarbonate
concentration to whatever level one likes with this technique.
In such a system, there is no limitation on bicarbonate delivery.
Indeed, Graefe and coworkers raised plasma bicarbonate con-
centration to 33 mEq/liter over 4 hours of dialysis using a high-
mass-transfer dialysis membrane, with a bath bicarbonate con-
centration of 35 mEq/liter [361. This degree of acute alkalemia is
probably not warranted, however. When used now, the goal is
generally to increase postdialysis bicarbonate concentration to
25 to 29 mEq/liter. This level should result in a subsequent
predialysis bicarbonate concentration in the range of 20 to 24
mEq/liter.
From the viewpoint of acid balance, however, it makes little
difference whether the bath contains acetate or bicarbonate.
Table 3 presents the balance considerations for bicarbonate
dialysis. In this example, I again assume arbitrarily that 240
mEq of alkali must be gained per dialysis to maintain balance.
Bicarbonate delivery during dialysis is determined, as noted
earlier, by the dialysance of this anion and the transmembrane
concentration gradient. This gradient diminishes as dialysis
progresses because plasma bicarbonate concentration rises
continually. To estimate the change in this gradient, we have
assumed that the added bicarbonate is distributed in a volume
of fluid equivalent to 50% body weight, on a minute-by-minute
basis. This space of distribution assumes that over one-half the
administered bicarbonate is consumed by titration of nonbicar-
bonate buffers. Whether this assumption is valid is unknown,
but again, the general conclusion holds regardless of the specif-
ic kinetics or space of distribution. In this example, bath
bicarbonate concentration is set at 32 mEq/liter. Given these
conditions, excess alkali will be delivered if the predialysis
plasma bicarbonate concentration is less than 20 mEq/liter,
whereas alkali delivery will be insufficient if the predialysis
plasma bicarbonate concentration is greater than 22 mEq/liter.
In a system with these specifications, plasma bicarbonate
concentration before dialysis will hover at approximately 21
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Table 3. Acid balance with a bicai jonate-containing dialysis bath:
Theoretic considerations
A. Alkali required = 240 inmols/dialysis
B. Dialysis specifications:
1. Bath HC03 = 32 mEq/L
2. DHCO3- = 150 mI/mm
3. Duration = 4 hrs
Plasma HC03
Initial Final Net alkali Net alkali-240
mEqIL mmols
16 26.3 360 120
18 27.0 315 75
20 27.7 270 30
22 28.4 225 —15
24 29.5 180 —60
mEq/liter in a patient with this alkali requirement. At that level,
acid balance will be maintained just as it is in the case of acetate
dialysis.
Gotch and colleagues studied net alkali gain in 8 patients
during the first week of dialysis with a bicarbonate-containing
bath [21]. Endogenous acid production was estimated from
protein catabolic rate as before, and lactate and 3-hydroxybu-
tyrate losses were estimated from the serum concentrations and
the dialysance of these anions. At the end of the week,
hydrogen ion balance was minus 175 mEq, equivalent to a net
gain of 175 mEq of bicarbonate (Table 4). Bicarbonate concen-
tration rose (as would be expected with negative acid balance),
but the increase in extracellular bicarbonate stores accounted
for only 30% of the estimated net alkali gain. Thus, either 70%
of the excess alkali was consumed by titration of nonbicarbon-
ate buffers, or estimated acid production was incorrect. As I
noted earlier, studies in normal individuals and experimental
animals have shown that 50% to 60% of administered alkali is
consumed in titrating nonbicarbonate buffers [10—121; thus,
these authors' estimate of acid production probably is close to
the mark. It is also possible that the alkali delivery stimulated
organic acid production. Their measurements of lactate and 3-
hydroxybutyrate loss do not support this idea, nor do the
observations by Ward and coworkers [221, but further work is
needed to determine this point with certainty. Gotch, Sargent,
and Keen raise the possibility that bone buffers might account
for the "alkali deficit," but they have no evidence either for or
against this hypothesis [21]. In my view, the alkali retention in
these patients simply reflects the upward adjustment in predial-
ysis serum bicarbonate concentration induced by the shift from
acetate to bicarbonate dialysis. A similar study carried out after
predialysis bicarbonate concentration stabilizes on bicarbonate
dialysis could easily answer the question of whether some
slowly equilibrating body buffer compartment is being retitrat-
ed. There is no evidence to date for such a compartment in
patients on dialysis therapy. And if such a compartment does
not participate in hydrogen ion economy in this setting, then
acid balance will be maintained regardless of the dialysis
technique. With bicarbonate dialysis, one trades off postdialysis
alkalemia for the avoidance of predialysis acidosis. In the
studies shown in Table 4, postdialysis pH was 7.49, and
bicarbonate concentration was 29 mEq/liter.
I have talked thus far about machine-patient interactions.
Table 4. Cumulative H balance in 8 patients during the first week of
bicarbonate dialysis (three 4-hr treatments)a
Acid in
1. Endogenous acid productionb 352 30 (SE)
2. Lactate loss 55 6
3. 3-hydroxybutyrate loss 37 12
Total 444 mmols
Alkali in
1. Bicarbonate delivery
Hydrogen ion balance
618 77
—175 45
a From Ref. 21.
b Calculated as 0.77 times protein catabolic rate.
Obviously, endogenous acid production can vary in a given
patient or among patients. It is likely that some of the variability
in predialysis bicarbonate concentration among dialysis pa-
tients is due to fluctuations in endogenous acid production as
well as to differences in dialysis membranes or duration of
dialysis. Studies in normal individuals have demonstrated a
correlation between variations in endogenous acid production,
induced by variations in diet, and steady-state serum bicarbon-
ate concentration [371.
Implications for dialysis therapy
The final question is whether the mild metabolic acidosis
present in dialysis patients adds significantly to dialysis morbid-
ity and mortality. Is the patient with a predialysis bicarbonate
concentration of 15 mEq/liter and a pH of 7.30 worse off than a
patient with a predialysis bicarbonate concentration of 22 mEq/
liter and a pH of 7.40? As I've attempted to show in this Forum,
the difference is probably unimportant with regard to bone
demineralization. Bone disease related specifically to metabolic
acidosis has not emerged as a problem in dialysis patients. On
the other hand, there may be other adverse consequences. In
children, acidemia retards growth [191. Other effects are less
clear, however. Cardiac contractility is diminished by acidosis,
but the effect is only notable at pH values less than 7.20 [38].
Ventricular irritability might be increased as well [39]. The
combination of a low pH and low bicarbonate is known to
impede potassium entry into cells acutely [40], but whether the
gradual fluctuations in pH and bicarbonate concentration oc-
curring in patients on hemodialysis increase the likelihood of
symptomatic hyperkalemia is unknown. Patients who have
lower bicarbonate concentrations do not appear to have more
generalized symptoms than do patients with higher bicarbonate
concentrations. To my knowledge, no one has shown a correla-
tion between plasma bicarbonate and survival or well-being on
dialysis. Unless a specific morbidity can be identified, there
appears to be little reason for attempting to increase bicarbon-
ate concentration in adult hemodialysis patients.
I have limited my discussion today to hemodialysis, but of
course the same principles hold for peritoneal dialysis [41]. The
steady-state plasma bicarbonate concentration in such patients
depends on the interplay between endogenous acid production
and net alkali gain during dialysis. A major difference, from an
acid-base perspective, between chronic ambulatory pentoneal
dialysis (CAPD) and hemodialysis is that, with the former
treatment, alkali is administered continually. Thus there is no
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interdialytic period during which body buffers are titrated by
endogenous acids. If buffer disequilibrium occurs, for example
in bone, major differences should emerge when CAPD patients
are compared with hemodialysis patients. Thus far, the only
difference is that plasma bicarbonate concentration is slightly
higher in CAPD than in hemodialysis patients in some, but not
all, reports [41].
I have not included a discussion of carbon dioxide diffusion
across the dialysis membrane in this review. In the most
commonly used systems, a significant amount of CO2 is lost
during dialysis [23, 42], whereas when a closed-system, bath-
regenerating cartridge is used, CO2 is actually gained from the
bath during dialysis [43]. These CO2 fluxes have a significant
impact on ventilation, but they do not influence acid balance.
Questions and answers
DR. JEROME P. KASSIRER: The measurements you have used
are fairly imprecise. In particular, values for endogenous acid
production are gross estimates, and one could easily miss 5 or
even 10 mmol of acid accumulation per day, which over a
period of years could amount to a substantial acid accumula-
tion. Is there any corollary evidence of acid accumulation over
time? For example, is bone carbonate disproportionately re-
duced in patients who have been on dialysis for 5 to 10 years?
DR. GENNARI: There are no data to answer this question, but
of course it goes to the heart of the issue. Is there a sustained
buffer dysequilibrium in chronic dialysis patients? I think not.
To recapitulate the essence of my argument, the rise in bicar-
bonate with dialysis, and its gradual fall in the interdialytic
period, support the notion that bicarbonate is reflecting other
buffers in the body. In settings in which bicarbonate doesn't
reflect acid balance, its concentration is low and stable, and
acid retention is relentless. In addition, the lack of evidence of
bone disease specifically related to acidosis even in long-term
dialysis patients argues against continued carbonate consump-
tion. Can I exclude acid retention based on my analysis? Of
course not, but I think it is very unlikely. It would be interesting
to compare bone carbonate in long-term dialysis patients with
previous observations in patients with untreated uremic acido-
sis, but I think that if acidosis per se were a problem in dialysis
patients, we all would have seen the problem by now. I refer
you to the case presented here. Despite 8 years of metabolic
acidosis, he is working full-time in an occupation that requires
some physical exertion. He feels well and has no clinical bone
disease.
DR. KASSIRER: So is it your belief that a patient with
advanced renal failure is in positive hydrogen-ion balance
before he or she is dialyzed and in acid balance after?
DR. GENNARI: Based on my analysis, I believe that further
acid retention does not occur after dialysis is initiated. Whether
the carbonate consumed in titrating retained acid before dialysis
is started is regenerated is another question. Careful balance
studies in stable patients before and after beginning dialysis are
required to answer this question. In the absence of any data, my
speculation is that only partial repair of lost carbonate occurs. I
know of no signal other than alkalemia for the bone to replenish
carbonate stores, and only transient alkalemia occurs
postdialysis.
DR. JORDAN J. COHEN: You indicated that acetate levels in
the blood rise rapidly at the onset of dialysis and reach a steady
state determined by the acetate level in the bath. You also
indicated that plasma bicarbonate concentration during dialysis
is fairly stable. If acetate is being picked up continuously during
the dialysis and not incrementing acetate concentration in the
plasma, then it must be converted to bicarbonate, which is then
lost in the bath. So the net result of all this is represented by the
residual increment in plasma acetate at the end of dialysis.
Can't we just look at that increment and judge directly how
much net alkali has been gained without invoking assumptions
about acetate and bicarbonate dialysance and the like?
In other words, wouldn't it be simpler to estimate the net
increment in alkali gained by the dialysis procedure by just
multiplying the residual increment in acetate concentration by
the space of distribution for this anion?
DR. GENNARI: Your approach is of course a reasonable one,
although it is simply observational and has no predictive power.
Moreover, one still needs to estimate a space of distribution for
administered acetate, and for bicarbonate if its concentration
changes during the dialysis. The approach I outlined today has
predictive power. If one knows the characteristics of the kidney
used, one can estimate the expected rates of bicarbonate and
acetate transfer. I did not mean to imply, however, that only
one technique was available for assessing net alkali gain. I used
existing data to make my point that net alkali addition is
importantly influenced by the predialysis bicarbonate
concentration.
DR. COHEN: According to your analysis, the predialysis
bicarbonate concentration could be increased by reducing the
dialysance of bicarbonate. Assuming it were desirable to in-
crease bicarbonate concentration, does this strategy make any
sense?
DR. GENNARI: No. One cannot reduce the dialysance of
bicarbonate without reducing the dialysance of the other sub-
stances we are trying to remove. In the early days of acetate
dialysis, membranes were less efficient, and plasma bicarbonate
concentrations were higher. The cost was longer dialysis treat-
ments, and no one wants to return to that situation.
DR. JOHN 1. HARRINGTON: Patients in chronic renal failure
are in positive acid balance by approximately 20 mmol/day
during the last years of their progressive renal failure. If studies
were carried out in the first 2 or 3 weeks of dialysis rather than
in the chronic steady state of dialysis, you might be able to see a
difference in net alkali or acid balance. This approach would be
an indirect way of looking at bone carbonate stores. Have any
such studies been performed?
DR. GENNARI: No. As I indicated earlier, such studies have
not been carried out. I agree that the results would be of
considerable interest.
DR. RONALD D. PERRONE (Division of Nephro!ogy,
NEMCH): John, in the beginning part of your talk you likened
the chronic renal failure patient on dialysis to a patient with
proximal renal tubular acidosis, in whom there is no net
accumulation of acid. In one sense the situation of chronic
dialysis is different in that there is a net accumulation of acid for
44 hours, followed by a 4-hour period of retitration, whereas in
proximal RTA the daily acid load would be rapidly excreted.
Could there be a deleterious effect of acid accumulation in this
interval?
DR. GENNARI: I don't think there is anything specifically
deleterious about acid accumulation in the interdialytic period,
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as compared to any other setting in which acid is retained. The
accumulating acid titrates body buffers. Bicarbonate is one of
these buffers, and we can observe its concentration falling in the
interdialytic period. As I stated earlier, the change in bicarbon-
ate concentration reflects its participation in the buffer process.
During dialysis, the alkali pool is replenished and is available
for titration in the next interdialytic period.
DR. PERRONE: Is there any information about how long bone
would take to reconstitute itself after titration of endogenous
acid?
DR. GENNARI: The only information I am familiar with is the
recent work of Bushinsky and coworkers [44]. These investiga-
tors studied calcium and proton fluxes in cultured mouse
calvaria. They found that bone buffering in these cultures was
rapid either when acid or alkali was added to the medium.
Calcium left the bone cells in response to acid addition, and it
reentered bone when alkali was added. These effects were
apparent both at 3 hours and at 24 hours. Whether these bone
cultures are an appropriate model of the response of long bone
in the intact organism remains to be seen, although recent
studies in intact rats indicate that a bone buffer response to acid
administration is evident within 24 hours [45].
DR. ANDREW LEVEY (Division of Nephrology, NEMCIJ):
Your analysis suggests that patients are in acid-base balance
whether the dialysate contains acetate or bicarbonate, even
though the plasma bicarbonate concentration is slightly higher if
bicarbonate is the buffer. However there are differences in acid-
base parameters during the dialysis treatment, and some have
suggested that patients have fewer untoward symptoms during
dialysis with bicarbonate-containing dialysate. Would you com-
ment on these differences?
DR. GENNARI: I have deliberately avoided a discussion of
patient symptoms. One can find evidence in support of whatev-
er stance one wishes to take on this issue. Acetate administra-
tion to human subjects without renal failure produces no
untoward symptoms [20, 27]. In patients on dialysis, some
investigators are convinced that bicarbonate dialysis is associ-
ated with fewer symptoms [6, 36]. On the other hand, two
recent double-blind studies failed to show any major differ-
ences, except in the occasional patient who has problems
metabolizing acetate [46, 47].
DR. VINCENT CANZANELLO (Fellow in Nephrology,
NEMCH): Regarding the results of blood gas specimens ob-
tained from hemodialysis access sites, do you believe the type
of vascular access (for example, primary side-to-side or end-to-
side versus a synthetic arteriovenous fistula) is important?
DR. GENNARI: No. We measured P02 in all the samples
obtained in our patients. The mean value obtained was 92 14
(SD) mm Hg. Only 6 of the 48 P02 values were less than 80 mm
Hg, and therefore we felt we had the equivalent of aterial blood.
DR. NIcoLAos E. MADIAS: Careful observations have docu-
mented the validity of employing blood from the arteriovenous
fistula for determining the values for arterial blood gases [48].
DR. HARRINGTON: One argument that the acetate advocates
have used is that there is a subgroup of "acetate-intolerant"
patients. Acetate levels may rise to 15 mmol/liter in these
patients, and it is argued that patients are more likely to be
symptomatic during dialysis. Can you comment on this?
DR. GENNARI: Dr. Fitzgibbons and his coworkers have
reported preliminary observations in a double-blind crossover
comparison between bicarbonate and acetate dialysis [47].
They studied a subgroup of acetate-intolerant patients who
were identified because of their symptoms; in these patients,
the decrease in bicarbonate between the beginning and end of
dialysis suggested a problem with acetate conversion to bicar-
bonate. As I mentioned earlier, these workers found that
bicarbonate dialysis reduced symptoms only in this subgroup of
patients. Unfortunately, they identified their acetate-intolerant
patients by symptoms, so one cannot draw any conclusions
concerning whether acetate intolerance is always associated
with symptoms. Vinay and coworkers used the pattern of
plasma bicarbonate during dialysis to estimate the incidence of
acetate intolerance in hemodialysis patients [49]. In a prelimi-
nary report, they found that 18% of their patients were acetate
intolerant by their criteria. The authors did not correlate acetate
intolerance with untoward symptoms during dialysis, however.
DR. COHEN: John, I certainly agree with you that there is
little evidence to suggest that the mild degree of acidosis
characteristic of dialysis patients is harmful, particularly in the
absence of persistently positive hydrogen-ion balance. The fact
remains, however, that nature picked 24 mEq/liter as the
bicarbonate concentration around which acid balance is nor-
mally maintained, at least at sea level. Not being able to detect
or to document any deleterious effect of mild degrees of
acidosis dosen't mean that some unwanted consequences might
not accumulate, especially in view of the very long stretches of
time during which dialysis patients are now exposed to a low
bicarbonate level. My question is, if you wanted to design a
strategy that would allow chronic dialysis patients to hover
around a bicarbonate of 24 mEq/liter while enjoying the advan-
tages of high-mass-transfer kidneys, what would you do?
DR. GENNARI: It is virtually impossible to achieve a bicar-
bonate concentration in the range of 24 mEq/liter using acetate
dialysis with the dialysis membranes presently available. Thus,
bicarbonate dialysis would be required if that were your goal.
Even with bicarbonate dialysis, however, one would have to
produce considerable postdialysis alkalemia to maintain a pre-
dialysis bicarbonate concentration in the 22 to 24 mEq/liter
range. Alkalemia in itself might be associated with symptoms
and, in theory, it could exacerbate tissue calcium phosphate
deposition. If maintenance of a stable normal plasma bicarbon-
ate concentration is your goal, then CAPD with appropriate
dietary management is the only acceptable form of therapy. I
would submit, however, that it makes little difference whether
your plasma bicarbonate concentration is 20 or 24 mEq/liter, so
long as acid balance is maintained.
DR. KASSIRER: Maybe we have been too worried about small
alterations in fluid, electrolyte, and acid-base equilibrium.
Although it is true that normal individuals live within an
extremely narrow range of plasma electrolytes, plasma bicar-
bonate concentrations, and blood pHs, it may not matter much
if they are off the mark by a few percent. A reduction of 4 or 5
mEq per liter in bicarbonate doesn't seem particularly harmful;
neither does a fall in serum potassium of 1 mEq/liter or a
potassium deficit of 100 to 200 mEq.
DR. COHEN: John, one price that patients do pay by having
chronic metabolic acidosis is hyperventilation. I wouldn't argue
that this is a very important issue but would merely point out
that dialysis patients with a low bicarbonate have a persistent
stimulus to ventilation which, under some circumstances, might
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be burdensome.
DR. GENNARI: One would be hard pressed to make a case
that the mild hyperventilation seen in dialysis patients is bad.
The mean PCO2 in our patients before dialysis was 34 mm Hg;
the range was 28 to 41 mm Hg. These values represent the
response to the trough bicarbonate level, and therefore PCO2 is
probably higher most of the time. To my knowledge, no ill
effects of PCO2 values in this range have been noted in humans.
DR. KASSIRER: I must admit your hypothesis has a sensible
ring. If patients on dialysis for long periods do not develop
hyperparathyroidism or osteomalacia, their bones remain in-
tact. If there were positive acid balance of a sufficient amount
over a period of time, you would expect these patients to
develop a substantial osteopenia, which most do not.
DR. HARRINGTON: The problem with measuring bone carbon-
ate has been that it has always been very complicated to
measure. Are there better ways of doing it now to directly
answer the question of how much acid is buffered by bone?
DR. GENNARI: To my knowledge there is no good way to
assess the long-term effects of bone buffering, save for tissue
analysis. Noninvasive techniques have been developed to eval-
uate bone density, but these techniques would not be useful for
detecting whether bone carbonate stores (which are only a
small fraction of bone mineral) are reduced.
DR. SUSAN Hou (Division of Nephrology, Michael Reese
Hospital): If even the mild acidosis typically seen in patients
undergoing hemodialysis is bad for growth, do children grow
better when dialyzed with a bicarbonate bath?
DR. GENNARI: The question will probably never be an-
swered. Because of the evidence in renal tubular acidosis that
complete correction of acidemia can restore a normal growth
pattern in children [50], pediatric nephrologists have routinely
provided additional bicarbonate to children receiving hemodial-
ysis. Obviously, growth impairment in children on dialysis is a
multifactorial problem. The results of recent studies suggest
that children grow better if they are receiving CAPD therapy
than if they are hemodialyzed [51, 52]. There are clearly many
differences between these two therapies, but one difference in
these studies was that serum total CO2 was higher in the
patients receiving CAPD. In neither study, however, could the
improvement in growth be correlated with the serum total CO2
content.
DR. SERAFINO GARELLA (Division of Nephrology, Michael
Reese Hospital): Do you think that examining external calcium
balance would be another valid way of determining the pres-
ence of chronic positive acid balance and ongoing bone carbon-
ate titration in the hemodialysis patients? In studies of chronic
metabolic acidosis [17], external calcium balance was negative,
the calcium losses occurring primarily through the urine. In
anuric patients undergoing hemodialysis, calcium losses might
take place through the dialyzer, where they might be quantitat-
ed. Alternatively, calcium released from bones might deposit in
soft tissues. Could this phenomenon be responsible for the
extensive calcium deposits seen in some patients on chronic
hemodialysis? Are these the more acidemic patients?
DR. GENNARI: Calcium-balance studies, which would be
difficult to carry out in dialysis patients, would not answer the
question. We know already that the problem is primarily one of
calcium distribution within the body rather than external bal-
ance. Calcium is not lost during dialysis. Bath calcium concen-
tration is higher than serum ionized calcium by design; thus
calcium addition is assured during dialysis. This addition is
reflected by a transient elevation of serum calcium postdialysis.
The problem is where the calcium ends up—in bone or in soft
tissues. Many factors influence this distribution, including
parathyroid hormone and phosphate concentration, in addition
to pH. Unfortunately, we have no good way of measuring this
pattern of distribution other than to look at bone mineral
content. There is no evidence I know of to indicate that soft-
tissue calcium deposition is higher in patients with lower
bicarbonate levels. As I noted earlier, soft-tissue calcium
deposition may be promoted by alkalemia.
Reprint requests to Dr. F. John Gennari, Division of Nephrology,
D305 Given Bldg., University of Vermont College of Medicine, Burling-
ton, Vermont 05405, USA
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